SLU-PP-332

Other Research Peptides

aka SLU PP 332 · Pan-ERR agonist · ERRα/β/γ agonist

Compare

Formula

MW (Da)

Half-life

hours (preclinical, rodent)

Saves

Overview

SLU-PP-332 is an experimental small molecule (not a peptide). Primary reports describe it as a synthetic agonist of ERRα/β/γ, with highest potency for ERRα. Follow-on medicinal chemistry emphasizes that the parent compound lacks oral bioavailability, motivating development of orally active follow-up agonists. There is no approved human use.

Mechanism

SLU-PP-332 activates ERRα, ERRβ, and ERRγ, driving an oxidative and aerobic transcriptional program in muscle and other tissues. The foundational mouse work showed that some acute exercise-like transcriptional responses are ERRα-dependent. Exact quantitative EC50 values are not available in the accessible primary abstracts, so the mechanism is best described qualitatively as pan-ERR agonism with ERRα preference rather than a quantitative pharmacology table.

0

Vendors

—

no vendors yet

Lowest price

—

Reported benefits

Improved treadmill endurance and oxidative muscle fibers in mice

In mice, SLU-PP-332 increased oxidative type IIa muscle fibers and improved treadmill endurance, supporting its reputation as an "exercise mimetic" in preclinical models.

[slupp-pubmed-erra]

preclinical

Increased energy expenditure and reduced fat mass

Mouse work also reported increased whole-body energy expenditure, increased fatty-acid oxidation, reduced fat mass, and improved insulin sensitivity in obesity and metabolic-syndrome models.

[slupp-pmc-hf]

preclinical

Preclinical signal in experimental heart failure

Additional preclinical work reported benefit in experimental heart failure models, expanding the rodent therapeutic-signal envelope beyond pure exercise mimicry.

[slupp-pmc-hf]

preclinical

Reported side effects

No human safety dataset
anecdotal
There is no human safety dataset in the reviewed sources. Chronic cardiometabolic effects in humans are unknown, and translational pharmacokinetics are uncertain.
Doping-potential flag
preclinical
Anti-doping researchers now explicitly discuss pan-ERR agonists such as SLU-PP-332 as having doping potential, which underscores performance-misuse concern without proving therapeutic efficacy or safety.

Dosing notes

In the foundational mouse exercise-mimetic study, mice received 50 mg/kg intraperitoneally, either as a single acute dose before treadmill testing or as chronic twice-daily dosing over 10 days. Human dosing is unspecified.

Research use only. Information on this page is editorial reference, not medical or dosing advice. Always consult qualified medical guidance before use.

Storage

Unspecified in authoritative sources reviewed. Research-grade small-molecule handling per supplier: dry, dark storage; protect from moisture and light.

Vendors carrying SLU-PP-332

No approved vendors are listing this peptide yet. Check back later or browse the full vendor directory.

Discussion

Ask, answer, and vote on questions about SLU-PP-332.

No questions yet. Be the first to ask.

References

[slupp-pubmed-erra]
SLU-PP-332 pan-ERR agonist (foundational pharmacology)
Authors per PubMed entry · PubMed
Source
[slupp-pmc-hf]
SLU-PP-332 in experimental heart failure and metabolic models
Authors per PMC entry · PubMed Central
Source
[slupp-pubmed-doping]
Pan-ERR agonists and doping potential
Authors per PubMed entry · PubMed
Source

Reported benefits

Improved treadmill endurance and oxidative muscle fibers in mice

Increased energy expenditure and reduced fat mass

Preclinical signal in experimental heart failure

No human safety dataset

Doping-potential flag

Discussion